Tyber Medical Granted FDA Clearance on Distal Radius Plating System

Tyber Medical Expands Its Extensive Plating Portfolio with FDA Approval of Distal Radius Plating System for Fractured Radius, Ulna and Hand Bones

Summation

  •  They recognized the need for an additional locking head size to accomplish this in the flexor tendon and narrow volar plates, and now we get to add that locking mechanism to our portfolio.
  • Tyber Medical’s Distal Radius Plating System maintains stability and orientation in the anteroposterior plane utilizing a dynamic grouping of plate length options, offered in titanium or stainless steel.
  • Additionally, the enhanced ergonomic design delivers a solution to reduce flexor tendon irritation, a common post operative concern,” said Tyber Medical CEO and President Jeff Tyber.

Tyber Medical, LLC, a leading orthopedic device manufacturer providing private label orthopedic implants for the trauma, extremity, and spine markets, received a U.S. Food and Drug Administration (FDA) 510(k) clearance for its new Distal Radius Plating System. Tyber Medical’s novel design covers a wide range of fractures, fusions, non-unions, malunions, or osteotomies of the radius, ulna, and hand. “The Tyber Medical Distal Radius System provides an innovative approach to address one of the most common fractures. Additionally, the enhanced ergonomic design delivers a solution to reduce flexor tendon irritation, a common post operative concern,” said Tyber Medical CEO and President Jeff Tyber.

Tyber Medical’s Distal Radius Plating System maintains stability and orientation in the anteroposterior plane utilizing a dynamic grouping of plate length options, offered in titanium or stainless steel. Tyber Medical’s Chief Technology Officer, David Hannah, said, “our engineering team did a great job keeping the design under the watershed line while maintaining low prominence and the ability to reach the radial styloid. They recognized the need for an additional locking head size to accomplish this in the flexor tendon and narrow volar plates, and now we get to add that locking mechanism to our portfolio.”

Other FDA News of Interest

Justice Department and FDA Announce Federal Multi-Agency Task Force to Curb the Distribution and Sale of Illegal E-Cigarettes

"Unauthorized e-cigarettes and vaping products continue to jeopardize the health of Americans – particularly children and adolescents – across the country," said Acting Associate Attorney General Benjamin C. Mizer. "This interagency Task Force is dedicated to protecting Americans by combatting the unlawful sale and distribution of these products. And the establishment of this Task Force makes clear that vigorous enforcement of the tobacco laws is a government-wide priority."

Tris Pharma Receives U.S. FDA Approval for Once-Daily ONYDA XR (clonidine hydrochloride) Extended-Release Oral Suspension, the First-and-Only Liquid Non-Stimulant ADHD Medication

ONYDA XR is indicated for the treatment of ADHD as monotherapy or as adjunctive therapy to approved CNS stimulant medications in pediatric patients six years and older. The first non-stimulant ADHD medication, with nighttime dosing, adds to Tris Pharma’s established portfolio of leading ADHD therapies and reinforces company's commitment to individuals with ADHD.

Indica Labs Receives FDA Clearance for HALO AP Dx Digital Pathology Platform for Use with Hamamatsu Images Acquired with the NanoZoomer® S360MD Slide Scanner

Indica Labs, an industry leader in AI-powered digital pathology solutions, and Hamamatsu Photonics K.K., a pioneer in whole slide imaging systems, announce that the...

By using this website you agree to accept Medical Device News Magazine Privacy Policy